BAXTER INTERNATIONAL INC. Funds and ETFs Baxter International Inc.
Equities
BAX
US0718131099
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 35.24 USD | -0.54% |
|
-2.44% | -8.85% |
| 05-13 | Baxter International's Clinolipid Injection Approved for Expanded Use in US | MT |
| 05-10 | TD Cowen Downgrades Baxter International to Hold From Buy, Price Target is $40 | MT |
ETFs positioned on Baxter International Inc.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.04% | 9 M€ | +9.94% | - | |
| 0.04% | 391 M€ | +8.80% | - | |
| 0.04% | 1,166 M€ | +0.26% | - | |
| 0.04% | 607 M€ | +0.05% | - | |
| 0.03% | 205 M€ | -.--% | ||
| 0.03% | 306 M€ | +5.95% | - | |
| 0.03% | 39 M€ | +5.31% | - | |
| 0.03% | 1 M€ | +3.03% | - | |
| 0.03% | 45 M€ | 0.00% | - | |
| 0.02% | 29 M€ | -.--% | - | |
| 0.02% | 322 M€ | +13.88% | - | |
| 0.02% | 17 M€ | +2.84% | - | |
| 0.02% | 17 M€ | +4.20% | - | |
| 0.02% | 105 M€ | +3.54% | - | |
| 0.02% | 32 M€ | +0.82% | - | |
| 0.01% | 6 M€ | +3.89% | ||
| 0.01% | 34 M€ | +3.53% | - | |
| 0.01% | 6 M€ | -4.26% | - | |
| 0.01% | 8 M€ | +0.60% | - | |
| 0.01% | 756 M€ | +0.15% | - | |
| 0.01% | 54 M€ | +0.52% | - | |
| 0.01% | 2 M€ | +3.16% | - |
Baxter International Inc. specializes in the development, manufacturing and marketing of medical devices and medications intended for healthcare professionals. Net sales break down by family of products as follows:
- medicines and medical devices (33.8%): products intended for treating hemophilia (substitution clotting factors) and immune deficiencies (multi-purpose immunoglobins), and used in intensive care (human albumin) and biosurgery (fibrin adhesive, surgical gel, bone substitutes, hemostatic compresses, etc.);
- kidney dialysis drugs and equipment (30.1%);
- systems for delivering medications and intravenous therapy (15.2%): used in the fields of anesthesia, oncology (chemotherapy and radiation), parenteral nutrition, etc.;
- other (20.1%).
Export accounts for 52.7% of net sales.
Calendar
2024-05-15
- BofA Securities Health Care Conference
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
35.24
USD
Average target price
46.47
USD
Spread / Average Target
+31.86%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -8.85% | 17.96B | |
| -5.51% | 181B | |
| +2.33% | 112B | |
| -3.62% | 67.92B | |
| +1.52% | 50.1B | |
| +8.06% | 44.27B | |
| +9.39% | 40.41B | |
| +23.35% | 31.95B | |
| +0.67% | 25.82B | |
| +17.27% | 25.29B |
- Stock Market
- Equities
- BAX Stock
- Funds and ETFs Baxter International Inc.
